A Survey of Breast Cancer Patients With Metastatic Bone Disease Receiving Oral Ibandronate

Roche

Status: Completed

Conditions: Metastatic Breast Cancer

Study type: Observational

Funder types: Industry

Identifiers

NCT02528747

ML22421

Details and patient eligibility

About

This observational, multicenter survey is designed to assess the efficacy of oral ibandronate in adults with breast cancer and metastatic bone disease. Data on the use of ibandronate in clinical practice will be collected from Hungarian patients.

Enrollment: 582 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adults at least 18 years of age
• Histologically confirmed breast cancer with bone metastasis
• Receiving or indicated for the tablet formulation of ibandronate according to the summary of product characteristics (SmPC) and local labeling

Exclusion criteria

• Contraindication to ibandronate according to SmPC
• Ongoing participation in any trial evaluating the efficacy and/or safety of ibandronate

Trial design

582 participants in 1 patient group

Study population

Description:

Breast cancer patients with metastatic bone disease